NovoCure LimitedNVCRNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +20.54% | +11.91% | +5.62% | +7.81% | +8.11% |
| Gross Profit Growth | +26.25% | +11.12% | +1.41% | +2.30% | +3.44% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.79% | +2.81% | +3.59% | +3.38% | +3.37% |
| Weighted Average Shares Diluted Growth | +0.79% | +2.81% | +3.59% | +3.38% | +3.37% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +98.28% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +32.37% | +82.13% | +99.46% | +27.10% | +13.01% |
| Inventory Growth | -8.04% | -6.90% | -0.57% | -100.00% | -100.00% |
| Asset Growth | +8.26% | +11.36% | +2.78% | +11.39% | -35.18% |
| Book Value per Share Growth | -1.42% | -2.03% | -6.75% | -8.48% | -8.56% |
| Debt Growth | +14.61% | +17.05% | +3.71% | +18.10% | -57.56% |
| R&D Expense Growth | -5.70% | +4.22% | +1.60% | +4.14% | +18.93% |
| SG&A Expenses Growth | +41.83% | +6.15% | +7.07% | +4.54% | -20.17% |